137 related articles for article (PubMed ID: 19903903)
21. Uses of telomerase peptides in anti-tumor immune therapy.
Li H; Katik I; Liu JP
Methods Mol Biol; 2007; 405():61-86. PubMed ID: 18369818
[TBL] [Abstract][Full Text] [Related]
22. Telomerase-specific T-cells kill pancreatic tumor cells in vitro and in vivo.
Schmidt J; Ryschich E; Sievers E; Schmidt-Wolf IG; Büchler MW; Märten A
Cancer; 2006 Feb; 106(4):759-64. PubMed ID: 16369992
[TBL] [Abstract][Full Text] [Related]
23. Identification of a new cytotoxic T-cell epitope p675 of human telomerase reverse transcriptase.
Huang G; Geng J; Wang R; Chen L
Cancer Biother Radiopharm; 2012 Nov; 27(9):600-5. PubMed ID: 22917214
[TBL] [Abstract][Full Text] [Related]
24. Vaccine therapy of established tumors in the absence of autoimmunity.
Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
[TBL] [Abstract][Full Text] [Related]
25. Efficient eradication of subcutaneous but not of autochthonous gastric tumors by adoptive T cell transfer in an SV40 T antigen mouse model.
Bourquin C; von der Borch P; Zoglmeier C; Anz D; Sandholzer N; Suhartha N; Wurzenberger C; Denzel A; Kammerer R; Zimmermann W; Endres S
J Immunol; 2010 Aug; 185(4):2580-8. PubMed ID: 20644173
[TBL] [Abstract][Full Text] [Related]
26. Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer.
Zhang Q; Yang X; Pins M; Javonovic B; Kuzel T; Kim SJ; Parijs LV; Greenberg NM; Liu V; Guo Y; Lee C
Cancer Res; 2005 Mar; 65(5):1761-9. PubMed ID: 15753372
[TBL] [Abstract][Full Text] [Related]
27. B cell-deficient mice are highly resistant to Leishmania donovani infection, but develop neutrophil-mediated tissue pathology.
Smelt SC; Cotterell SE; Engwerda CR; Kaye PM
J Immunol; 2000 Apr; 164(7):3681-8. PubMed ID: 10725726
[TBL] [Abstract][Full Text] [Related]
28. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
[TBL] [Abstract][Full Text] [Related]
29. Novel prostate acid phosphatase-based peptide vaccination strategy induces antigen-specific T-cell responses and limits tumour growth in mice.
Saif JM; Vadakekolathu J; Rane SS; McDonald D; Ahmad M; Mathieu M; Pockley AG; Durrant L; Metheringham R; Rees RC; McArdle SE
Eur J Immunol; 2014 Apr; 44(4):994-1004. PubMed ID: 24338683
[TBL] [Abstract][Full Text] [Related]
30. Adoptive T cell immunotherapy of human uveal melanoma targeting gp100.
Sutmuller RP; Schurmans LR; van Duivenvoorde LM; Tine JA; van Der Voort EI; Toes RE; Melief CJ; Jager MJ; Offringa R
J Immunol; 2000 Dec; 165(12):7308-15. PubMed ID: 11120866
[TBL] [Abstract][Full Text] [Related]
31. Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression.
DuPage M; Cheung AF; Mazumdar C; Winslow MM; Bronson R; Schmidt LM; Crowley D; Chen J; Jacks T
Cancer Cell; 2011 Jan; 19(1):72-85. PubMed ID: 21251614
[TBL] [Abstract][Full Text] [Related]
32. Telomerase in cancer immunotherapy.
Liu JP; Chen W; Schwarer AP; Li H
Biochim Biophys Acta; 2010 Jan; 1805(1):35-42. PubMed ID: 19751801
[TBL] [Abstract][Full Text] [Related]
33. Adoptive cell therapy of prostate cancer using female mice-derived T cells that react with prostate antigens.
Yi H; Yu X; Guo C; Manjili MH; Repasky EA; Wang XY
Cancer Immunol Immunother; 2011 Mar; 60(3):349-60. PubMed ID: 21088965
[TBL] [Abstract][Full Text] [Related]
34. Adoptive T-cell therapy of prostate cancer targeting the cancer stem cell antigen EpCAM.
Deng Z; Wu Y; Ma W; Zhang S; Zhang YQ
BMC Immunol; 2015 Jan; 16(1):1. PubMed ID: 25636521
[TBL] [Abstract][Full Text] [Related]
35. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
36. Truncated TERT mRNA transfected dendritic cells evoke TERT specific antitumor response in vivo.
Qiu J; Lil GW; Sui YF; Sun YJ; Huang YY; Si SY; Ge W; Song HP
Hepatogastroenterology; 2007; 54(75):681-7. PubMed ID: 17591041
[TBL] [Abstract][Full Text] [Related]
37. Induction of human cytotoxic T lymphocytes specific for prostate-specific antigen.
Xue BH; Zhang Y; Sosman JA; Peace DJ
Prostate; 1997 Feb; 30(2):73-8. PubMed ID: 9051144
[TBL] [Abstract][Full Text] [Related]
38. Vaccine-instructed intratumoral IFN-γ enables regression of autochthonous mouse prostate cancer in allogeneic T-cell transplantation.
Hess Michelini R; Manzo T; Sturmheit T; Basso V; Rocchi M; Freschi M; Listopad J; Blankenstein T; Bellone M; Mondino A
Cancer Res; 2013 Aug; 73(15):4641-52. PubMed ID: 23749644
[TBL] [Abstract][Full Text] [Related]
39. The STEAP1(262-270) peptide encapsulated into PLGA microspheres elicits strong cytotoxic T cell immunity in HLA-A*0201 transgenic mice--A new approach to immunotherapy against prostate carcinoma.
Herrmann VL; Wieland DE; Legler DF; Wittmann V; Groettrup M
Prostate; 2016 Apr; 76(5):456-68. PubMed ID: 26715028
[TBL] [Abstract][Full Text] [Related]
40. Sequential administration of the native TERT572 cryptic peptide enhances the immune response initiated by its optimized variant TERT(572Y) in cancer patients.
Vetsika EK; Papadimitraki E; Aggouraki D; Konsolakis G; Mela ME; Kotsakis A; Christou S; Patramani S; Alefantinou M; Kaskara A; Christophyllakis C; Kosmatopoulos K; Georgoulias V; Mavroudis D
J Immunother; 2011; 34(9):641-50. PubMed ID: 21989412
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
